Mark your calendar: April 10, 2026. That is the day the FDA is expected to announce its decision on orforglipron, Eli Lilly's oral GLP-1 pill. If approved, it will be the first non-semaglutide oral weight loss pill to hit the market — and the first one you can take like a normal medication, with food, at any time of day, no fasting gymnastics required.
The original PDUFA date was March 28. The FDA pushed it back two weeks, citing the need for additional review of manufacturing data. That delay spooked some investors but is actually routine — the agency wants to make sure Lilly can produce enough pills to avoid the shortage disasters that plagued Ozempic and Mounjaro in 2023 and 2024. The clinical data itself was never in question.
Nine days out, this is shaping up to be the most consequential GLP-1 approval since Wegovy launched in 2021. Here is what is happening and what it means for you.
Why Orforglipron Is a Big Deal
Let us be direct: orforglipron solves the two biggest complaints about current GLP-1 medications.
No more injections. Yes, oral Wegovy already exists. But orforglipron is different in a way that matters enormously for daily life. Oral Wegovy (oral semaglutide) requires you to take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating or drinking anything else. Every single morning. Miss the window or eat too early, and the drug does not absorb properly.
Orforglipron has none of that. It is a small molecule, not a peptide, which means it survives your stomach acid without any special absorption tricks. Take it with breakfast. Take it with dinner. Take it with coffee at 3 PM. It does not care. For anyone who has tried oral Wegovy and found the fasting window annoying, impractical, or impossible to maintain — this is the fix.
It beat oral Wegovy head-to-head. In Eli Lilly's Phase 3 ATTAIN trials, the 60mg dose of orforglipron produced 14.7% body weight loss at 72 weeks. That is slightly less than injectable Wegovy (15-17%) but competitive with oral semaglutide's 15.1% at 68 weeks — and orforglipron achieved those numbers without any dosing restrictions. When you factor in real-world adherence (people actually taking the pill consistently because it is easier), the effective weight loss could be even closer. A medication you actually take every day beats a theoretically better one you skip three times a week.
Novo Nordisk Is Already Panicking
If you needed proof that Novo Nordisk sees orforglipron as an existential threat to their oral Wegovy franchise, look at what they did yesterday.
On March 31 — literally the day before we are writing this — Novo Nordisk launched a direct-to-consumer Wegovy subscription program. For $249 per month on a 12-month commitment, patients can get Wegovy delivered to their door with telehealth consultations included. No insurance required. That is a massive price cut from the $1,350 list price and a clear signal that Novo is trying to lock in customers before orforglipron launches.
They also rolled out Wegovy HD, a higher 7.2mg dose that showed 20.7% total body weight loss in clinical trials. That number puts it ahead of orforglipron on raw efficacy — but it is still an injection, and the subscription program for Wegovy HD has not been announced yet.
The strategy is transparent: give patients a reason to start Wegovy now and commit to a year-long plan, so they are less likely to switch when orforglipron becomes available. It is a defensive play, and the fact that Novo is making it tells you everything about how seriously they take the competitive threat.
What This Means for Your Wallet
Here is the part that actually matters to most people: two competing oral GLP-1 pills means a price war, and price wars are great for consumers.
Before orforglipron, Novo Nordisk had a near-monopoly on semaglutide. They could charge $1,350 per month for injectable Wegovy and $1,200 for the oral version because there was no real alternative. The Wegovy subscription at $249/month is the first crack in that wall — and it happened before orforglipron is even approved.
Eli Lilly has not announced orforglipron pricing, but Wall Street analysts expect a launch price between $400 and $600 per month. As a small molecule (not a biologic), orforglipron is dramatically cheaper to manufacture than peptide-based drugs. That cost advantage gives Lilly room to undercut Novo on price while still making healthy margins.
Insurance coverage should follow quickly. Both UnitedHealthcare and Cigna have signaled they will cover orforglipron for obesity if approved, joining their existing GLP-1 coverage. Medicare will cover orforglipron starting in July under the Bridge program at the same $50/month copay as Wegovy and Zepbound. If your employer plan already covers GLP-1 medications, orforglipron will likely be added to the formulary within 60-90 days of approval.
The bottom line: over the next 6-12 months, the out-of-pocket cost of GLP-1 therapy is going to come down significantly across the board. Competition does what no amount of Congressional hearings ever could.
Should You Wait or Switch?
This is the question we are getting most often, so here is our honest take based on your situation:
If you are happy on your current injectable GLP-1 (Wegovy, Zepbound, Ozempic, Mounjaro) — stay put. There is no clinical reason to switch from an injectable that is working well. Injectables still produce slightly higher weight loss on average, and once-weekly dosing is actually simpler than daily for some people. Do not fix what is not broken.
If you are on oral Wegovy and struggling with the fasting requirement — orforglipron is worth waiting for. This is the clearest use case. If you are missing doses because you cannot maintain the 30-minute fasting window, or if it is interfering with other morning medications, orforglipron eliminates that problem entirely. Talk to your prescriber now so you are ready to switch if the FDA approves.
If you have been avoiding GLP-1 therapy because of needles — this is your moment. Orforglipron is a regular pill. No injections, no fasting, no special storage requirements. If needle aversion has been your barrier, the barrier is about to disappear.
If cost is your primary concern — wait 6 months. The price war between Novo and Lilly is just getting started. Prices will come down further as both companies fight for market share. The Medicare Bridge program launches in July. Employer plans are expanding coverage. By Q4 2026, the GLP-1 market will look very different from today.
What Happens Next
April 10 is the decision date, but it is not the launch date. If the FDA approves orforglipron, Eli Lilly will need 4-8 weeks to ramp up distribution. Realistically, patients could start filling prescriptions in late May or early June 2026.
We will publish a full breakdown the day the FDA announces its decision, including pricing details, insurance coverage analysis, and head-to-head comparisons with every other GLP-1 on the market.
Our Take
The GLP-1 landscape is about to fundamentally change. For the first time, patients will have a genuine choice between two competing oral options — one from Novo Nordisk with a proven track record but an annoying fasting requirement, and one from Eli Lilly that works like a normal pill. Add in the injectable options, the Medicare Bridge program, and falling prices across the board, and 2026 is shaping up to be the year that GLP-1 therapy becomes accessible to the mass market.
For the full deep dive on orforglipron's clinical data, dosing, and side effects, check out our [orforglipron guide](/guides/orforglipron). If you are trying to decide between current options while you wait, our [Ozempic vs. Wegovy comparison](/compare/ozempic-vs-wegovy) breaks down the differences, and our [best GLP-1 providers ranking](/best) tracks who offers the most competitive pricing and best patient experience.
We will be covering the April 10 decision live. Stay tuned.